Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00221299 · ClinicalTrials.gov registry record · Phase 4
Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
A Phase 4 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT00221299 is a Phase 4 study that has completed, run by University of California, Davis. The registered enrollment target is 60 participants.
The verdict
NCT00221299, a Phase 4 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study is to learn if one year of treatment with parathyroid hormone (PTH), either alone or with risedronate, will increase the thickness of the bones in the hip and spine in subjects with osteoporosis from chronic low dose steroid use. During the second year, the study will also look at whether taking risedronate will preserve the bone thickness created by one year of rhPTH 1-34 treatment.
Interventions
- DRUG Risedronate
- DRUG Parathyroid Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00221299
The ClinicalTrials.gov registry entry for NCT00221299 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risedronate is the first listed.
NCT00221299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00221299 about?
NCT00221299 is a clinical study titled "Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use". The purpose of the study is to learn if one year of treatment with parathyroid hormone (PTH), either alone or with risedronate, will increase the thickness of the bones in the hip and spine in subjects with osteoporosis from chronic low dose steroid use. During the second year, the study will also l...
What is the current status of trial NCT00221299?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2005-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00221299?
The interventions under investigation include: Risedronate (DRUG), Parathyroid Hormone (DRUG).
Who is sponsoring clinical trial NCT00221299?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.